Your browser doesn't support javascript.
loading
[Severe or life-threatening interactions between antiretrovirals and non-HIV drugs]. / Interacciones graves o potencialmente letales entre antirretrovirales y otros medicamentos.
Manzardo, Christian; Tuset, Montserrat; Miró, Jose M; Gatell, Jose M.
Afiliación
  • Manzardo C; Servicio de Enfermedades Infecciosas, Hospital Clínic-IDIBAPS/Universidad de Barcelona, Barcelona, España. Electronic address: cmanzard@clinic.ub.es.
  • Tuset M; Servicio de Enfermedades Infecciosas y Departamento de Farmacia, Hospital Clínic-IDIBAPS/Universidad de Barcelona, Barcelona, España.
  • Miró JM; Servicio de Enfermedades Infecciosas, Hospital Clínic-IDIBAPS/Universidad de Barcelona, Barcelona, España.
  • Gatell JM; Servicio de Enfermedades Infecciosas, Hospital Clínic-IDIBAPS/Universidad de Barcelona, Barcelona, España.
Enferm Infecc Microbiol Clin ; 33(7): e15-30, 2015.
Article en Es | MEDLINE | ID: mdl-24913990
ABSTRACT
Highly active antiretroviral therapy has helped to improved control of the HIV infection, and has led to a progressively older population with the infection having a life expectancy quite similar to that of the general population. On the other hand, it is also known that HIV infection, even in patients with undetectable viral loads and good immunity, carries an increased cardiovascular risk, as well as an increased incidence of certain cancers. Therefore, the majority of HIV-infected patients receive several drugs (either prescribed by the physician or self-administered) combined with antiretrovirals. This article reviews the interactions between antiretrovirals and other drugs that can cause significant damage to patients, or even be life-threatening and of whom clinicians, especially those not directly treating HIV-infected patients, should be aware. A review is also presented on the implications of interactions between antiretrovirals and other drugs in special situations, such as the co-administration with cytostatics, immunesuppressants used in solid organ transplantation, or patients receiving new treatments for hepatitisC. Generally, combinations with two nucleos(t)ide reverse transcriptase inhibitors and raltegravir (or in the near future, dolutegravir) are those with less potential for clinically significant interactions.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antirretrovirales / Interacciones Farmacológicas Límite: Humans Idioma: Es Revista: Enferm Infecc Microbiol Clin Asunto de la revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antirretrovirales / Interacciones Farmacológicas Límite: Humans Idioma: Es Revista: Enferm Infecc Microbiol Clin Asunto de la revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Año: 2015 Tipo del documento: Article